Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "neurological-disorder"

27 News Found

Siemens Healthineers expands its offerings in India
Medical Device | September 20, 2022

Siemens Healthineers expands its offerings in India

Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite


AbbVie submits NDA for treatment of advanced Parkinson’s disease
Biotech | May 21, 2022

AbbVie submits NDA for treatment of advanced Parkinson’s disease

If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs


AbbVie to showcase neuroscience portfolio at AAN 2022 annual meeting
Biotech | March 29, 2022

AbbVie to showcase neuroscience portfolio at AAN 2022 annual meeting

AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia


Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting
News | March 25, 2022

Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting

Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment


Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases
Biotech | March 09, 2022

Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases

Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders


Medtronic gets USFDA approval of spinal cord stimulation therapy
Medical Device | January 25, 2022

Medtronic gets USFDA approval of spinal cord stimulation therapy

Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone


Biogen exercises option with Ionis for spinal muscular atrophy
Biotech | January 05, 2022

Biogen exercises option with Ionis for spinal muscular atrophy

Biogen paid Ionis a US $ 60 million one-time upfront payment